THC Farmaceuticals Inc
OTC:CBDG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alfa Laval AB
STO:ALFA
|
SE |
|
MT Educare Ltd
NSE:MTEDUCARE
|
IN |
|
Assa Abloy AB
STO:ASSA B
|
SE |
|
L
|
Long Hau Corp
VN:LHG
|
VN |
|
B
|
Beijing Bewinner Communications Co Ltd
SZSE:002148
|
CN |
|
CITIC Telecom International Holdings Ltd
HKEX:1883
|
HK |
|
Kyodo Public Relations Co Ltd
TSE:2436
|
JP |
|
Vitasoy International Holdings Ltd
HKEX:345
|
HK |
|
S
|
Skeena Resources Ltd
NYSE:SKE
|
CA |
THC Farmaceuticals Inc
Total Equity
THC Farmaceuticals Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
THC Farmaceuticals Inc
OTC:CBDG
|
Total Equity
$2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
UniFirst Corp
NYSE:UNF
|
Total Equity
$2.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
VSE Corp
NASDAQ:VSEC
|
Total Equity
$1.4B
|
CAGR 3-Years
47%
|
CAGR 5-Years
32%
|
CAGR 10-Years
20%
|
|
|
Copart Inc
NASDAQ:CPRT
|
Total Equity
$9.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
27%
|
CAGR 10-Years
30%
|
|
|
Aurora Innovation Inc
NASDAQ:AUR
|
Total Equity
$2.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Cintas Corp
NASDAQ:CTAS
|
Total Equity
$4.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
THC Farmaceuticals Inc
Glance View
THC Farmaceuticals, Inc. engages in the research and development of cannabis pharmaceutical products. The company is headquartered in Scottsdale, Arizona. The company went IPO on 2012-08-22. The firm through its subsidiary CBDual Biotechnology Corp., a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The firm is engaged cannabis formulations, edibles, and delivery systems of cannabis. The company manufactures and markets cannabis extract products made from cannabis. The firm's facility is located in Southern California. The company provides access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. The firm is focusing on the research of psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations.
See Also
What is THC Farmaceuticals Inc's Total Equity?
Total Equity
2.8m
USD
Based on the financial report for Sep 30, 2022, THC Farmaceuticals Inc's Total Equity amounts to 2.8m USD.
What is THC Farmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 1Y
-13%
Over the last year, the Total Equity growth was -13%.
